There have been limited studies directly comparing the long-term efficacy between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in treatment-naïve chronic hepatitis B (CHB).
Out of 345 CHB patients who received first line therapy with ETV (n = 200) or TDF (n = 145) in a cohort, 210 patients were analyzed using propensity score matching, at a ratio of 1:1.
Two groups showed no difference in baseline characteristics. During the follow-up of 12 months, HBV DNA levels were similarly suppressed in both groups (ETV vs. TDF; −5.01 vs. -5.242 log10IU/mL, P = 0.559). At month 12, both groups showed no difference in terms of the serologic, biochemical and virologic (VR) response. In multivariate analysis, the initial virologic response at 3 months (IVR-3) was independent factor for VR at 1 year. During the long-term follow-up, HBV DNA levels were more strongly suppressed by TDF than ETV in hepatitis B e antigen (HBeAg) positive patients (P = 0.035), especially with high viral load (P = 0.012), although there was no significant difference in overall VR between two groups. The type of antivirals was not an independent factor for long-term VR.
Although either ETV or TDF, overall, may show a comparable long-term antiviral efficacy in treatment-naïve CHB, TDF might be better regimen than ETV in the subgroup of HBeAg-positive CHB, especially with a higher HBV DNA levels.
Safileas M, Lyqidakis NJ, Manti C. Hepatitis B today. Hepatogastroenterology. 2007;54:545–8.
Liaw YF. Hepatitis B, virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther. 2006;11:669–79. PubMed
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85. CrossRef
Lee JM, Kim HJ, Park JY, Lee CK, Kim DY, Kim JK, et al. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther. 2009;14:705–12. PubMed
Murat K, Fatma S, Yesim A, Nail O, Ahmet TE, Deniz S. Head-to-head comparison of two years efficacy of entecavir and tenofovir in patients with treatment-naïve chronic hepatitis B-The real life data. Hepatogastroenterology. 2015;62:982–6.
López Centeno B, Collado Borrell R, Pérez Encinas M, Gutiérrez García ML, Sanmartin FP. Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B. Farm Hosp. 2016;40:279–86. PubMed
Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, et al. Efficay and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatol Res. 2016. doi: 10.1111/hepr.12743.
- Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
Ji Won Park
Kyeong Min Kwak
Sung Eun Kim
Myoung Kuk Jang
Ki Tae Suk
Dong Joon Kim
Sang Hoon Park
Myung Seok Lee
Hyoung Su Kim
Choong Kee Park
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II